Loboda Danuta, Sarecka-Hujar Beata, Nowacka-Chmielewska Marta, Szoltysek-Boldys Izabela, Zielinska-Danch Wioleta, Gibinski Michal, Wilczek Jacek, Gardas Rafal, Grabowski Mateusz, Lejawa Mateusz, Malecki Andrzej, Golba Krzysztof S
Department of Electrocardiology and Heart Failure, Medical University of Silesia in Katowice, 40-635 Katowice, Poland.
Department of Basic Biomedical Science, Faculty of Pharmaceutical Sciences in Sosnowiec, Medical University of Silesia in Katowice, 41-200 Sosnowiec, Poland.
Life (Basel). 2024 Sep 2;14(9):1105. doi: 10.3390/life14091105.
This study evaluated the relationship of non-invasive arterial stiffness parameters with an individual 10-year risk of fatal and non-fatal atherosclerotic cardiovascular disease (ASCVD) events in the cohort post-coronavirus disease 2019 (COVID-19). The study group included 203 convalescents aged 60.0 (55.0-63.0) and 115 (56.7%) women. The ASCVD risk was assessed as low to moderate to very high based on medical history (for 62 participants with pre-existing ASCVD/diabetes/chronic kidney disease in the entire cohort) or calculated in percentages using the Systemic Coronary Risk Evaluation 2 (SCORE2) algorithm based on age, sex, smoking status, systolic blood pressure (BP), and non-high-density lipoprotein cholesterol (for 141 healthy participants). The stiffness index (SI) and reflection index (RI) measured by photoplethysmography, as well as pulse pressure (PP), calculated as the difference between systolic and diastolic BP, were markers of arterial stiffness. Stiffness parameters increased significantly with the increase in ASCVD risk in the entire cohort. In 30 (14.8%) patients in the low- to moderate-risk group, the median SI was 8.07 m/s (7.10-8.73), RI 51.40% (39.40-65.60), and PP 45.50 mmHg (40.00-57.00); in 111 (54.7%) patients in the high-risk group, the median SI was 8.70 m/s (7.40-10.03), RI 57.20% (43.65-68.40), and PP 54.00 mmHg (46.00-60.75); and in 62 (30.5%) patients in the very-high-risk group, the median was SI 9.27 m/s (7.57-10.44), RI 59.00% (50.40-72.40), and PP 60.00 mmHg (51.00-67.00). In healthy participants, the SI ≤ 9.0 m/s (sensitivity of 92.31%, area under the curve [AUC] 0.686, < 0.001) based on the receiver operating characteristics was the most sensitive variable for discriminating low to moderate risk, and PP > 56.0 mmHg (sensitivity of 74.36%, AUC 0.736, < 0.001) was used for discriminating very high risk. In multivariate logistic regression, younger age, female sex, PP ≤ 50 mmHg, SI ≤ 9.0 m/s, and triglycerides < 150 mg/dL had the best relationship with low to moderate SCORE2 risk. In turn, older age, currently smoking, PP > 56.0 mmHg, RI > 68.6%, and diastolic BP ≥ 90 mmHg were related to very high SCORE2 risk. In conclusion, arterial stiffness is significantly related to ASCVD risk in post-COVID-19 patients and can be helpful as a single risk marker in everyday practice. Cut-off points for arterial stiffness parameters determined based on SCORE2 may help make individual decisions about implementing lifestyle changes or pharmacological treatment of ASCVD risk factors.
本研究评估了2019冠状病毒病(COVID-19)康复队列中无创动脉僵硬度参数与个体10年发生致命和非致命性动脉粥样硬化性心血管疾病(ASCVD)事件风险的关系。研究组包括203名康复者,年龄为60.0(55.0 - 63.0)岁,其中115名(56.7%)为女性。根据病史(整个队列中有62名患有既往ASCVD/糖尿病/慢性肾病的参与者)将ASCVD风险评估为低到中到非常高,或者对于141名健康参与者,使用基于年龄、性别、吸烟状况、收缩压(BP)和非高密度脂蛋白胆固醇的系统性冠状动脉风险评估2(SCORE2)算法以百分比计算。通过光电容积脉搏波描记法测量的僵硬度指数(SI)和反射指数(RI),以及计算为收缩压与舒张压之差的脉压(PP),是动脉僵硬度的标志物。在整个队列中,僵硬度参数随着ASCVD风险的增加而显著增加。在低到中度风险组的30名(14.8%)患者中,SI中位数为8.07 m/s(7.10 - 8.73),RI为51.40%(39.40 - 65.60),PP为45.50 mmHg(40.00 - 57.00);在高风险组的111名(54.7%)患者中,SI中位数为8.70 m/s(7.40 - 10.03),RI为57.20%(43.65 - 68.40),PP为54.00 mmHg(46.00 - 60.75);在非常高风险组的62名(30.5%)患者中,SI中位数为9.27 m/s(7.57 - 10.44),RI为59.00%(50.40 - 72.40),PP为60.00 mmHg(51.00 - 67.00)。在健康参与者中,基于受试者工作特征曲线,SI≤9.0 m/s(敏感性为92.31%,曲线下面积[AUC]为0.686,<0.001)是区分低到中度风险最敏感的变量,PP>56.0 mmHg(敏感性为74.36%,AUC为0.736,<0.001)用于区分非常高风险。在多因素逻辑回归中,年龄较小、女性、PP≤50 mmHg、SI≤9.0 m/s和甘油三酯<150 mg/dL与低到中度SCORE2风险的关系最佳。相反,年龄较大、当前吸烟、PP>56.0 mmHg、RI>68.6%和舒张压≥90 mmHg与非常高的SCORE2风险相关。总之,动脉僵硬度与COVID-19康复患者的ASCVD风险显著相关,并且在日常实践中作为单一风险标志物可能会有所帮助。基于SCORE2确定的动脉僵硬度参数的截断点可能有助于就实施生活方式改变或对ASCVD风险因素进行药物治疗做出个体决策。